Gossamer Bio, Inc. (GOSS)
9.83
+0.55
(+5.93%)
USD |
NASDAQ |
Oct 13, 14:59
Gossamer Bio Free Cash Flow (Quarterly) : -41.39M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -41.39M |
| March 31, 2026 | -38.72M |
| December 31, 2025 | -48.31M |
| September 30, 2025 | -36.17M |
| June 30, 2025 | -47.11M |
| March 31, 2025 | -39.75M |
| December 31, 2024 | -35.48M |
| September 30, 2024 | -32.03M |
| June 30, 2024 | 116.35M |
| March 31, 2024 | -52.30M |
| December 31, 2023 | -33.42M |
| September 30, 2023 | -34.49M |
| June 30, 2023 | -38.25M |
| March 31, 2023 | -52.99M |
| December 31, 2022 | -47.83M |
| September 30, 2022 | -37.03M |
| June 30, 2022 | -48.94M |
| March 31, 2022 | -53.64M |
| Date | Value |
|---|---|
| December 31, 2021 | -40.59M |
| September 30, 2021 | -42.56M |
| June 30, 2021 | -47.59M |
| March 31, 2021 | -59.70M |
| December 31, 2020 | -36.99M |
| September 30, 2020 | -45.23M |
| June 30, 2020 | -42.84M |
| March 31, 2020 | -52.81M |
| December 31, 2019 | -44.67M |
| September 30, 2019 | -36.82M |
| June 30, 2019 | -38.19M |
| March 31, 2019 | -28.12M |
| December 31, 2018 | -25.34M |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | -4.219M |
| December 31, 2017 | -5.721M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| United Therapeutics Corp. | 202.20M |
| Arbutus Biopharma Corp. | -5.952M |
| Kura Oncology, Inc. | -63.20M |
| ACADIA Pharmaceuticals, Inc. | 95.69M |
| Alnylam Pharmaceuticals, Inc. | 292.04M |